BHA Has Been a Probable Carcinogen for 30 Years. The FDA Is Finally Acting.

A preservative linked to cancer in animal studies has been sitting in American breakfast cereals, chips, and frozen meals for decades. The National Toxicology Program (NTP) classified butylated hydroxyanisole (BHA) as "reasonably anticipated to be a human carcinogen" back in the 1990s. It kept appearing on ingredient labels. In February 2026, the FDA finally launched a formal post-market safety reassessment. The same science, 30 years later, now apparently worth examining.

Context

BHA is a synthetic antioxidant preservative. Food manufacturers add it to products containing fats and oils to prevent them from going rancid. It shows up in breakfast cereals, potato chips, frozen meals, cookies, ice cream, processed meats, bread, and snack bars. Products marketed specifically to children are not exempt; BHA appears in popular cereal and snack brands across grocery store shelves.

The ingredient is listed on labels, but it's easy to miss buried among a long list of additives. Most consumers scanning a box of cereal are not cross-referencing the NTP's list of anticipated human carcinogens. They have no reason to expect that a substance cleared by the FDA decades ago carries a warning that was also decades in the making.

The EU moved ahead of the United States on this. BHA is banned or severely restricted for certain food applications in the European Union. This is part of a pattern that has played out repeatedly: titanium dioxide, brominated vegetable oil, and Red Dye No. 3 were all restricted abroad years before American regulators acted. According to reporting by Chemical & Engineering News, state-level regulatory activity targeting BHA is also building inside the US.

The Findings

The FDA's reassessment, launched in February 2026, is being directed under Health and Human Services Secretary Robert F. Kennedy Jr. The agency opened a public comment period with a deadline of April 13, 2026. Similar reassessments are planned for BHT (butylated hydroxytoluene, BHA's chemical cousin) and azodicarbonamide, a dough conditioner found in bread products.

The core of the concern comes from animal studies. Research has linked BHA to benign and malignant forestomach tumors as well as liver cancer in animal models. The mechanism involves how BHA metabolizes in the body: it breaks down into compounds that can damage DNA in certain biological environments. This metabolic pathway is the basis for the NTP's classification, which puts BHA in the same category as formaldehyde and acetaldehyde.

The NTP's classification, "reasonably anticipated to be a human carcinogen," is a specific designation. It does not mean confirmed. It means the science is substantial enough that the connection is not theoretical, and the evidence would not comfortably support a determination of safety.

The FDA's own reassessment documentation cites these same animal studies as the foundation for the review. That the agency is only now formally examining an additive that its own scientific counterparts flagged in the 1990s reflects how the regulatory system works. Post-market safety reviews require resources, political will, and institutional momentum. Until 2026, BHA had enough of none of those.

Food Navigator USA reported in February 2026 that the FDA framed the reassessment as part of a broader effort to review food chemicals with outdated safety data. US News & World Report noted that the FDA described the process as examining whether the original safety determinations for BHA still hold under current scientific standards.

What Experts Say

Kennedy's statement on the reassessment was direct. "This reassessment marks the end of the 'trust us' era in food safety," he said, referring to the long-standing practice of allowing additives approved under older standards to remain in the food supply without periodic review.

Critics of the US food additive system have pointed out for years that the GRAS (Generally Recognized as Safe) framework, under which many preservatives including BHA were originally approved, relies heavily on manufacturer-submitted safety data and does not require independent reassessment unless the FDA affirmatively initiates one. The February 2026 action is notable precisely because the FDA is taking that affirmative step.

Chemical & Engineering News reporting highlighted that state-level legislative action has added political pressure. Several states have introduced or passed bills targeting specific food additives, creating a patchwork of restrictions that food manufacturers would prefer to avoid. Federal action, even a slow reassessment, reduces that uncertainty.

What This Means for You

A few practical points matter here.

First, even if the FDA's reassessment concludes that BHA should be restricted or banned, that outcome is not imminent. Formal reassessments move through comment periods, scientific reviews, proposed rulemaking, and final rules. The process takes months to years. Consumers who want to reduce their exposure to BHA cannot rely on regulatory action arriving quickly.

Second, the NTP classification has been in place since the 1990s. The science is not new. What changed in 2026 is that the FDA decided to act on it. That decision gap, more than 30 years wide, is worth understanding when evaluating what the regulatory approval of any additive actually means.

Third, BHT (chemically similar to BHA and used in many of the same products) is next on the FDA's list for reassessment. If you are reviewing your exposure to BHA, BHT warrants the same attention.

The VeriFoods app lets you scan any product barcode and instantly see whether it contains BHA, BHT, or other additives flagged by health and regulatory bodies. Rather than parsing ingredient lists by hand or waiting for a regulatory process that has already taken 30 years to start, you can get a clear answer at the shelf. The app displays plain-language explanations of the health concerns associated with each additive, so you have the information you need to make your own call.

The comment period on the FDA's BHA reassessment closes April 13, 2026. The regulatory outcome will follow on its own timeline. What you eat in the meantime is a decision that doesn't have to wait.

Sources

1. FDA - "FDA Launches Assessment of BHA, a Common Food Chemical Preservative" - February 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-assessment-bha-common-food-chemical-preservative
2. Food Navigator USA - "FDA launches reassessment of BHA food preservative amid safety concerns" - February 11, 2026. https://www.foodnavigator-usa.com/Article/2026/02/11/fda-launches-reassessment-of-bha-food-preservative-amid-safety-concerns/
3. Chemical & Engineering News (ACS) - "FDA reassesses BHA safety as states target the preservative" - February 2026. https://cen.acs.org/policy/chemical-regulation/bha-fda-food-additive-reassessment/104/web/2026/02
4. US News & World Report - "FDA Reviews Safety of Food Preservative BHA Over Cancer Concerns" - February 11, 2026. https://www.usnews.com/news/health-news/articles/2026-02-11/fda-reviews-safety-of-food-preservative-bha-over-cancer-concerns